Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bayesian adaptive platform trial of MMRVAXPRO for prevention of COVID-19 in healthcare workers
2020-001402-38Phase 3Unknown
- Sponsor
- University College London
- Start
- May 2020
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19) comparing MMRVAXPRO vaccine with Placebo (2 arms). Primary endpoint: Symptomatic COVID-19 by day 60. Status: unknown.
02
Drugs
M-M-R II
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001402-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001402-38.